Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2019-11-13 Regulatory Filings
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., pursuant to SEC rules. It references a press release about hosting a third quarter 2019 financial results conference call. The document length is 2170 characters, which is relatively short and mainly serves as a notification of the upcoming earnings call rather than containing the financial results or detailed analysis itself. There is no substantive financial data or detailed report content present. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings and announcements that do not fit other specific report types.
2019-11-13 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about the publication of Phase 3 study results in a medical journal (JAMA). The document is short (2168 characters) and primarily serves as a regulatory filing to announce this event. It does not contain financial statements, detailed financial data, or management discussion. It is not an annual or quarterly report, nor an earnings release. It is not a proxy, governance, or capital structure document. The Form 6-K is a periodic report for foreign private issuers to disclose material information. Given the content and length, this fits best under Regulatory Filings (RNS) as a general announcement and compliance document rather than a full report or presentation.
2019-11-12 English
Regulatory Filings 2019
Regulatory Filings
2019-11-06 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about FDA approval of a drug, attached as Exhibit 99.1. The document is short (2161 characters) and primarily serves as a report of a material event rather than a full financial report. Form 6-K filings are periodic reports for foreign private issuers to disclose material information and are generally classified as Regulatory Filings (RNS) in this taxonomy. There is no detailed financial data or comprehensive report content here, just a notification and press release. Therefore, the appropriate classification is Regulatory Filings (RNS).
2019-11-04 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., pursuant to SEC rules. It includes a press release about a presentation at a conference but does not contain detailed financial statements or substantive financial data. The document length is short (2096 characters) and it primarily serves as a regulatory filing to report a press release event. There is no indication of an annual report, earnings release, or detailed financial report. According to the rules, such filings that do not fit other categories and are primarily regulatory announcements fall under Regulatory Filings (RNS).
2019-10-29 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, RedHill Biopharma Ltd., submitted to the SEC. It includes a press release about presenting new Phase 3 data at a medical conference. The document is short (2164 characters) and primarily serves as a regulatory update rather than a full financial report or detailed presentation. It does not contain financial statements or detailed analysis, nor is it an announcement of voting results, management changes, or capital activities. Form 6-K filings are typically used for current reports by foreign private issuers and often fall under general regulatory filings. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2019-10-28 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.